NCT04406610 is a Phase 1, PHASE2 clinical trial of GD2 CAR-T immunotherapy in Glioma of Brain, sponsored by Fuda Cancer Hospital, Guangzhou.

Who is sponsoring NCT04406610?

NCT04406610 is sponsored by Fuda Cancer Hospital, Guangzhou.

What drugs are being tested in NCT04406610?

Interventions in NCT04406610: GD2 CAR-T immunotherapy.

What condition does NCT04406610 study?

NCT04406610 studies Glioma of Brain, CAR-T Cell Immunotherapy.

Is NCT04406610 still recruiting?

NCT04406610 is currently withdrawn. Last updated 16 July 2020.

Last reviewed 2020-07-16 · How we verify

NCT04406610

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

Withdrawn Phase 1, PHASE2 Last updated 16 July 2020

What this trial tests

Phase 1, PHASE2 trial testing GD2 CAR-T immunotherapy in Glioma of Brain. Withdrawn.

Timeline

1 September 2015

Primary endpoint
15 August 2016

15 October 2016

Quick facts

Lead sponsor	Fuda Cancer Hospital, Guangzhou
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Start date	1 September 2015
Primary completion	15 August 2016
Estimated completion	15 October 2016

Drugs / interventions tested

GD2 CAR-T immunotherapy — full drug profile →

Conditions studied

Glioma of Brain — all drugs for Glioma of Brain →
CAR-T Cell Immunotherapy — all drugs for CAR-T Cell Immunotherapy →

Sponsor

Fuda Cancer Hospital, Guangzhou

Who can join

Adults 30 to 70, any sex, with Glioma of Brain or CAR-T Cell Immunotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors.
Boccalatte F, Mina R, Aroldi A, Leone S, et al · · 2022 · cited 17× · PMID 36291891 · DOI 10.3390/cancers14205108
Chimeric antigen receptor adoptive immunotherapy in central nervous system tumors: state of the art on clinical trials, challenges, and emerging strategies to addressing them.
Del Baldo G, Carai A, Mastronuzzi A. · · 2024 · cited 2× · PMID 38989708 · DOI 10.1097/cco.0000000000001076

Verify or expand the search:

Other recruiting trials for Glioma of Brain

Currently open trials in the same condition.

NCT03935685 — Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ · Phase 2 · active not recruiting
NCT03739372 — Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade · NA · active not recruiting
NCT03534050 — Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy · Phase 2, PHASE3 · recruiting
NCT03849430 — Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients · recruiting

Other Fuda Cancer Hospital, Guangzhou trials

Trials by the same sponsor.

NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04406610 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
Last refreshed: 16 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04406610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing